Phathom Pharmaceuticals announced that the company will present data from multiple studies for its first-in-class treatment VOQUEZNA including an oral presentation at Digestive Disease Week, DDW, 2024, being held May 18-21 in Washington, D.C. Phathom’s Phase 3 results evaluating the investigational use of VOQUEZNA in Non-Erosive Reflux Disease, NERD, will be featured in an oral presentation during the congress.1 In addition, poster presentations showcasing real-world evidence on suboptimal treatment patterns of newly diagnosed Erosive GERD patients treated with proton pump inhibitors, and an analysis highlighting high healthcare resource utilization costs associated with Erosive GERD, among other important clinical data updates and broader clinical sessions, will be showcased.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals sees cash runway through 2026
- Phathom Pharmaceuticals reports Q1 EPS ($1.42), consensus ($1.31)
- Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- Phathom Pharmaceuticals initiated with a Buy at Stifel
- Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Questions or Comments about the article? Write to editor@tipranks.com